FUSN Fusion Pharmaceuticals Inc.

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial.

$4.85  +0.15 (3.19%)
As of 12/06/2021 16:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  Canada
IPO date:  06/26/2020
Outstanding shares:  43,066,219
Average volume:  30,238
Market cap:   $202,411,229
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    36118A100
ISIN:        CA36118A1003
Sedol:      BJK0NH0
Valuation   (See tab for details)
PE ratio:   -4.51
PB ratio:   0.85
PS ratio:   239.26
Return on equity:   -31.32%
Net income %:   -9,124.82%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy